Costo- Efectividad Del Uso Profiláctico Del Factor Estimulante De Colonias De Granulocitos En Adultos Con Leucemia Linfoblástica Aguda en Colombia

详细信息    查看全文

• 作者：Elkin Javier Casadiego Rincó ; n ; MD MSc¹ ; ^{casavieja2032@gmail.com} ; Jorge Augusto D&iacute ; az Rojas ; PharmD MSc² ; Carlos Daniel Bermú ; dez ; MD³ (Haematologist) ; V&iacute ; ctor Prieto Mart&iacute ; nez ; Econ²
• 关键词：Granulocyte Colony-Stimulating Factor ; Filgrastim ; Pegfilgrastim ; Leukemia ; Cost- Effectiveness Analysis ; Febrile Neutropenia ; Colombia
• 刊名：Value in Health Regional Issues
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：Complete
• 页码：9-16
• 全文大小：1235 K
• 卷排序：11

文摘

To assess the cost-effectiveness of prophylactic administration of Granulocyte Colony-Stimulating Factor (G-CSF) compared with no use of it, during the induction phase of chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) in Colombia.MethodsA decision tree with a time horizon of 30 days was built under colombian health system perspective including only direct costs. The costs of procedures and medications were taken from official sources and an institution of national reference of oncology services. The safety and effectiveness data were taken from the literature and two Colombian cohorts with patients older than 15 years. The unit of outcome was the proportion of deaths avoided.ResultsBase-case results on a clinical trial indicate that using factor is a dominant strategy. The variable that most impacted the outcome was the incidence of febrile neutropenia. Considering a threshold of $22.228 USD in 80% of cases using factor was cost effective. However, the use of factor is not cost-effective for the country for incidences of febrile neutropenia > 48%. It was not possible to establish cost-effectiveness of pegfilgrastim because no information was found.ConclusionAs per Colombian data, the use of prophylactic factor under chemotherapeutic induction in adults with ALL, turns out to be not cost effective. The difference in the results suggests the need of a careful extrapolation of information from clinical trials (ideal world) for developing economic evaluations in Colombia.